1103390--2/21/2006--INTRABIOTICS_PHARMACEUTICALS_INC

related topics

{stock, price, operating}

{stock, price, share}

{provision, law, control}

{financial, litigation, operation}

{acquisition, growth, future}

{control, financial, internal}

We are currently a party to a securities litigation class action lawsuit, which, if determined adversely, could negatively affect or limit our strategic alternatives, our financial results or business. Directors, principal stockholders and affiliated entities beneficially own or control at least 48% of our capital stock outstanding and may be able to exert control over our activities, and the results of our operations and financial condition may suffer. The holders of our Series A preferred stock have rights that they could exercise against the best interests. of our common stockholders. Anti-takeover provisions in our charter documents and under Delaware law may make it more difficult to acquire us. Our stock price has been, and will be volatile, and the value of your investment may continue to decline. We may continue to incur net losses. We may not be able to complete the strategic alternative we initially elected to pursue, resulting in increased expenses and a delay in finally completing a selected alternative.

Full 10-K form ▸

1103390--2/21/2006--INTRABIOTICS_PHARMACEUTICALS_INC_/DE